INDV SEC Filings, Earnings & Splits

Supernus, Inc. announced an adjustment to the conversion rate of its 0.625% Convertible Senior Notes due 2031, increasing the rate from 24.0033 to 30.9355 shares per $1,000 principal due to a special dividend. No bondholders converted their bonds.

Indivior Pharmaceuticals filed a Form 8-K cover page disclosing a change of its principal executive office address from North Chesterfield, Virginia to Rockville, Maryland, effective November 2, 2026.

Indivior Pharmaceuticals issued a press release reporting its financial results for the period ended September 30, 2026, furnished as Exhibit 99.1 to the Form 8-K.

Indivior Pharmaceuticals filed its quarterly report on Form 10-Q for the period ending Q3 2026, accompanied by the standard CEO Sarbanes-Oxley certification signed by Chief Executive Officer Joseph Ciaffoni.

Indivior Pharmaceuticals filed a routine Form 8-K cover page with the SEC on October 15, 2026, containing only standard registrant identification and XBRL metadata with no substantive corporate event disclosed.

Indivior Pharmaceuticals filed a Form 8-K cover page dated October 6, 2026, with no substantive event details disclosed in the provided text.

Millennium Management LLC and affiliated entities filed a Schedule 13G disclosing beneficial ownership of Indivior Pharmaceuticals common stock, accompanied by a joint filing agreement.

Indivior Pharmaceuticals, Inc. filed an 8-K form with the SEC on September 17, 2026, covering a report date of September 16, 2026. The filing appears to be a routine cover page submission with no material event disclosed.

Indivior UK Ltd entered into a deed of variation and termination with Reckitt Benckiser Healthcare (UK) Ltd to terminate their copacker supply agreement earlier than originally planned, with the new termination date set for January 15, 2027. Indivior will pay various costs including under absorption impact, asset depreciation, equipment removal, redundancy, and incentive costs.

Indivior Pharmaceuticals and Supernus Pharmaceuticals announced a merger of equals via an all-stock transaction. Supernus stockholders will receive 1.5401 Indivior shares per Supernus share, and Indivior will pay a $1 billion special dividend to its stockholders before the merger closes.